$19.18
0.180.95%
Last update: Nov 11, 7:15 AM
NewAmsterdam Pharma Co NV
NAMSNASDAQ
NewAmsterdam Pharma fell 51.9% from $39.89 to $19.18, behind the S&P 500's +9.8%. Its worst day was Dec 3 (−14.0%), and its low came Nov 5 at $18.89.
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
NewAmsterdam Pharma closed at its highest level of the year, 3.9% above where the year started.
+2.5% · S&P 500 +0.7%
EPS of $-0.63 missed the $-0.38 estimate on $32,000.00 revenue (est. $4.3M).
Story events cover the past 12 months · Times ET
+1.5% · S&P 500 +0.5%
NewAmsterdam Pharma shares rose 9.1%, while the S&P 500 rose 2.9%.
+9.1% · S&P 500 +2.9%
EPS of $-0.40 beat the $-0.43 estimate on $3.0M revenue (est. $1.2M).
+12.5%, the year's best day · S&P 500 −0.3%
NewAmsterdam Pharma shares rose 9.0%, while the S&P 500 rose 0.8%.
+9.0% · S&P 500 +0.8%
EPS of $-0.52 missed the $-0.43 estimate on $3.7M revenue (est. $2.4M).
−0.5% · S&P 500 −0.2%
NewAmsterdam Pharma shares fell 11.1%, while the S&P 500 fell 0.5%.
−11.1% · S&P 500 −0.5%
NewAmsterdam Pharma shares fell 8.7%, while the S&P 500 fell 0.5%.
−8.7% · S&P 500 −0.5%
EPS of $-0.14 beat the $-0.45 estimate on $19.2M revenue (est. $7.4M).
+5.2% · S&P 500 +1.7%
Where it ended: a close of $19.18 on Nov 10, 2026. Up next: Q4 2026 earnings on Feb 17, 2027 (EPS est. $-0.41, revenue est. $14.7M).
Nothing in the past 12 months.
All NAMS dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for NAMS and SPY from Benzinga historical bars. Not investment advice.
